Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.

The addition of bevacizumab to chemotherapy for platinum-resistant (PL-R) ovarian cancer (OC) improved progression-free (PFS) but not overall survival (OS) in clinical trials. We explored real-world outcomes in Ontario, Canada, and compared survival in the pre- and post-bevacizumab era. Administrative databases were utilized to identify all patients treated with bevacizumab for PL-R OC. Time on treatment (ToT) was used as surrogate for PFS. Median OS was determined using the Kaplan-Meier method. Factors associated with ToT/OS were identified using a Cox proportional hazard model. A before and after comparative effectiveness analysis was performed to determine mOS for patients treated pre- and post-bevacizumab approval. From 2017 to 2019, 176 patients received bevacizumab. Median ToT was 3 months and OS was 11 months. Sixty-four percent received liposomal doxorubicin and 34% received paclitaxel. ToT (6 vs 3 months; HR 0.44; p < 0.0001) and OS (14 vs 9 months; HR 0.45; p = 0.0089) were longer with bevacizumab/paclitaxel. OS was not significantly different pre- and post-bevacizumab funding (8 vs 9 months; HR 1.01; 0.937). Median OS increased for those receiving paclitaxel (6 vs 11 months), but those in the post group were younger, more likely to have undergone primary surgery and had less co-morbidities. Real-world outcomes with bevacizumab in PL-R OC are inferior to those in the pivotal clinical trial. Survival has not significantly improved since funding became publicly available, indicating a substantial efficacy-effectiveness gap between trial and real-world outcomes. Median OS and ToT were significantly better when bevacizumab was given with paclitaxel. • We explored real-world outcomes with bevacizumab (bev)/chemotherapy for platinum-resistant ovarian cancer. • Median time on treatment (ToT) was 3 months and overall survival (OS) was 11 months. • ToT (6 vs 3 months; p < 0.0001) and OS (14 vs 9; p = 0.0089) were longer with bev/paclitaxel than bev/liposomal doxorubicin. • OS was not significantly different for patients treated pre- and post-bev approval (8 vs 9 months; HR 1.01; p = 0.937). • Post-approval OS increased for patients receiving bev/paclitaxel (6 vs 11 months). [ABSTRACT FROM AUTHOR]